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This retrospective study investigates if delays between the diagnosis of cancer of the oesophagus and surgical resection influence
long-term survival. Data held by the West Midlands Cancer Intelligence Unit on 800 patients who underwent oesophagectomy for a
diagnosis of cancer of the oesophagus or oesophagogastric junction between 1995 and 2000 were reviewed. Six hundred and thirty-
two patients treated with curative intention and who had not received neo-adjuvant treatment in the form of radio- or
chemotherapy were included in the analysis. The time interval between histological diagnosis and surgical resection was stratified into
four groups: less than 3, 3–6, 6–9 and more than 9 weeks. The Cox proportional hazard model was used to test for the
independent effect of delays. The results showed no difference in long-term survival according to the delay between histological
diagnosis and surgical resection. On multivariate analysis adverse prognostic factors were advanced age, incomplete resection and
lymph node involvement. Patients with a longer delay had a higher rate of complete tumour resection suggesting that they were
more appropriately selected for the surgical treatment approach. In conclusion we have found no evidence that shorter delays from
the date of histological diagnosis to surgical resection are beneficial to long-term survival.
British Journal of Cancer (2006) 95, 835–840. doi:10.1038/sj.bjc.6603333 www.bjcancer.com
Published online 12 September 2006
& 2006 Cancer Research UK
Keywords: oesophageal cancer; surgical resection; timing; delay; prognosis
                                             
Almost 7400 new cases of oesophageal cancer were diagnosed in
UK in 2000. In the same year about 6900 deaths owing to this type
of cancer were registered. The outlook for most patients diagnosed
with oesophageal cancer is poor with an overall 5-year survival of
about 8%. Only about one-third of patients undergo surgical
treatment as in the majority of patients the cancer is locally too
advanced or has already metastasised at the time of diagnosis
(McCulloch et al, 2003). Oesophagectomies carry one of the
highest postoperative mortality among elective surgical procedures
with a 30-day mortality of around 7% (O’Connell et al, 2004).
Unfortunately surgery in itself is not very effective, with 50% of
stage I patients and 80% of stage II patients dying within 5 years
and an overall cure rate from the small fraction of operable
patients being only around 20% (Gilbert et al, 2002; Gillison et al,
2002).
Not surprisingly several studies have shown that the ability to
achieve a complete resection of the tumour with uninvolved
margins on histological examination, defined by the American
Joint Committee on Cancer Classification as ‘R0-Resection’, is a
strong prognostic factor (Greene et al, 2002). Virtually no patients
with either microscopically (R1) or macroscopically (R2) residual
tumour are alive 5 years later, indeed most die within 2 years
(Dexter et al, 2001; Hofstetter et al, 2002). Preoperative
chemotherapy has been shown to reduce the number of involved
lymph nodes, decrease the size of the tumour and improve the rate
of complete resection in the responding group of patients (Kelson
et al, 1998; Medical Research Council Oesophageal Working Party,
2002), which led to the evaluation of multimodality treatment
approaches and the acceptance of neoadjuvant chemotherapy as
the present standard of care.
Although some retrospective studies imply that delays between
displaying first symptoms of the disease and establishing a
diagnosis of oesophageal cancer may adversely affect outcome,
no study has so far demonstrated a relation between short duration
of symptoms and early tumour stage or an increased ability to
achieve curative resection (Martin et al, 1997; Rothwell et al, 1997).
Driven by public expectations and NHS waiting time targets there
is increasing pressure to shorten the time from cancer diagnosis to
treatment, but literature on the impact of any service or physician-
related delay on outcome is scarce. The question if more timely
surgery amongst those with a diagnosis could make a difference
has not been addressed. In addition there are still concerns that a
delay to surgical resection owing to treatment with neoadjuvant
chemotherapy may be detrimental for the non-responding group
of patients (Richel and Vervenne, 2004).
This retrospective study investigates if delays from the time of
diagnosis to surgery impact on the long-term survival of patients
undergoing oesophageal resection for squamous cell carcinoma
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s(SCC) or adenocarcinoma (AC) of the oesophagus. All patients
evaluated in this study did not receive neoadjuvant chemotherapy.
As it would be ethically unacceptable to perform a prospective trial
of early versus delayed surgery and because neoadjuvant
chemotherapy is now regarded as the required standard of care
for the majority of patients with resectable carcinoma of the
oesophagus, future research is unlikely going to be able to address
this question.
METHODS
Study design
Approval for the study was obtained from the Birmingham Local
Research Ethics Committee. The West Midlands Cancer Intelli-
gence Unit (WMCIU) was approached for identification of patients
who underwent oesophagectomy for cancer of the oesophagus or
oesophagogastric junction (OGJ) between 1995 and 2000 without
having received neoadjuvant treatment in the form of chemo-
therapy or radiotherapy. These dates were chosen for two main
reasons: first to allow for 5-year follow-up data and secondly
because of a change of practice occurred in the UK towards giving
neo-adjuvant chemotherapy following presentation of the results
of the MRC OE02 Trial at the annual meeting of the American
Society of Clinical Oncologists in May 2001 (Clark, 2001).
In accordance with WMCIU guidelines all treating surgeons
were approached for permission to allow access to the records held
by the WMCIU. The abbreviated patient files were reviewed and
the following demographic and histopathological data collected:
date of diagnosis (defined as the day on which the tumour biopsy
was taken which resulted in the diagnosis of oesophageal cancer),
age at diagnosis, treating hospital, date of surgery, tumour site,
histological type and differentiation, pathological stage (pTNM),
completeness of resection, patient’s follow up status (alive or dead)
and date of death if applicable.
The time delay to surgery was calculated from the date of
diagnosis to the surgical resection date and categorised into four
groups: 0–21 days, 22–42 days, 43–63 days and more than 64
days. Location of the tumour was defined as upper-, middle-,
lower- third of the oesophagus or OGJ if the tumour was located
between 14–18cm, 19–34cm, 35–40cm and more than 40cm
from the incisors, respectively. Tumours were coded as ‘not
otherwise specified’ if the exact location could not be elicited.
Tumours located at the cardia or corpus of the stomach without
involvement of the lower oesophagus on histology, were dis-
regarded as stomach cancer. The tumour differentiation was taken
from the histopathology report and was recorded according to the
predominant area as well-, moderately- or poorly-differentiated
(Ibrahim, 2000). If the tumour was described as ‘well to
moderately’ or ‘moderate to poorly’ differentiated, the poorest
tumour differentiation was taken. The tumour, node and
metastasis classification according to the pathological report
(pTNM) was recorded (Sobin and Wittekind, 2002). Completeness
of resection was evaluated from the histopathology report and any
surgical notes and classified as either ‘complete resection’ (R0) or
‘microscopically or macroscopically incomplete resection’ (R1/R2).
Date of death was recorded as per death certificate. Median and
overall survival was calculated from the date of diagnosis. Patients
alive on the 1 September 2004 were censored on that date.
Data analysis
Baseline differences in prognostic or possible confounding factors
between the four different treatment delay groups were performed
by the w
2-test. Survival curves were calculated using the Kaplan–
Meier method and differences assessed by log-rank statistics. The
relationship between survival and the following prognostic factors
were evaluated by univariate analysis: age (less than 60 years,
60–70 or more than 70 years), gender, hospital type (University
Hospitals or District General Hospitals (DGH)), histological type
(AC or SCC), lymph node involvement (lymph node positive or
negative), location of tumour, differentiation, completeness of
resection and time interval from diagnosis to treatment (all as
defined above). The Cox proportional hazard model was used to
test for the independent effect of delays after adjusting for the
above variables and hazard ratios for survival were estimated with
95% confidence limits. Statistical analysis was performed with
SSPS for Windows Version 11.5.
RESULTS
Patients
The WMCIU identified 1260 patients with a diagnosis of
oesophageal cancer or cancer of the cardia who had a surgical
intervention for this diagnosis between 1995 and 2000. The
patients were registered under eight cardio-thoracic- and 21
general surgeons, two gastro-enterologists and general general
physicians. All but two general surgeons who had retired were
approached for permission to utilise cancer registry information
for the purpose of this study. Twenty consultants (64.5%)
responded and confirmed their agreement.
The records of 800 patients were reviewed. Patients were
excluded from further analysis for the following reasons: Surgery
not with curative intention: 52 patients; surgery for local recurrent
disease: one patient; treatment with neo-adjuvant chemotherapy in
MRC OE 02 Study (patients allocated to the surgery only arm were
included in the analysis): 17 patients; cancer located in the cardia
without involvement of the OGJ on histopathological examination:
22 patients; histology other than SCC or AC: 14 patients; date of
the upper gastro-intestinal endoscopy or original biopsy missing:
61 patients. All remaining 632 patients were included in the
analysis. Their demographic and tumour characteristics are
described in Table 1.
The male-to-female ratio was 2.5–1. Their median age was 67
years (range 21–89 years). About half of the patients were
operated in University Hospitals. In half of the patients the tumour
was located at the OGJ and in another third at the lower
oesophagus. The predominant histological type was AC and the
majority of tumours were moderate or poorly differentiated. The
commonest pathological tumour stage was pT3N1 (Stage III) in 338
patients (53%), the second commonest was pT2o r3N0 (Stage IIA)
in 159 patients (25%). In one-third of all oesophagectomies no
lymph nodes were involved and a complete resection was achieved
in 68% of operations.
Delays
The median time from diagnostic endoscopy to surgical resection
was 47 days and ranged from 0 to 287 days (Figure 1). Thirteen
percent of patients were operated within 3 weeks, 39% within
6 weeks, 72% within 9 weeks and 90% within 12 weeks. Patients
operated later after their diagnosis were of more advanced age
(P¼0.0255) and more likely operated at a University Hospital
(Po0.0001) than those treated sooner. On histology tumours
resected after a longer delay were more likely to be ACs
(P¼0.0008) and more likely to have been completely resected
(P¼0.0097) compared to tumours resected after a shorter delay
(Table 2). Patients operated after a longer delay were less likely to
have pathological stage IV disease (P¼0.012) (Figure 2). There
was no difference between complete resection rates at operations
performed at University hospitals and DGHs (70% and 66%,
respectively, P¼0.269). Patient’s gender, postoperative mortality,
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stumour location, tumour grade or lymph node status were not
significantly different in the four different delay groups.
Survival
Five hundred and thirty-nine patients (85%) were registered dead
and 93 patients censored on the 1 September 2004 for the Kaplan–
Meier survival analysis. Median follow-up was 6.5 years, range
3.7–9.7 years. The median survival of all patients was 15.4 months
and the 2-, 3 and 5-year survival rates were 33, 24 and 17.5%,
respectively.
Table 1 Characteristics of all patients (percentages in brackets)
Characteristics Number of patients (n¼632)
Age (years)
o60 171 (27.1)
60–70 229 (36.2)
470 232 (36.7)
Gender
Male 451 (71.4)
Female 181 (28.6)
Hospital type
University hospitals 326 (51.6)
DGHs 289 (45.7)
PrH 17 (2.7)
Tumour location
Upper 1/3 of oesophagus 4 (0.6)
Middle 1/3 of oesophagus 71 (11.2)
Lower 1/3 of oesophagus 210 (33.2)
Oesophago-gastric junction 324 (51.3)
Not specified 23 (3.6)
Histology
AC 475 (75.2)
SCC 157 (24.8)
Tumour differentiation
Well 57 (9)
Moderate 237 (37.5)
Poor 300 (47.5)
Not specified 38 (6)
Stage
0 5 (0.8)
I 43 (6.8)
II A 159 (25.2)
II B 43 (6.8)
III 338 (53.5)
IV 39 (6.2)
Not specified 5 (0.8)
LN status
LN –ve 210 (33.2)
LN +ve 417 (66)
Not specified 5 (0.8)
Resection
R0 432 (68.4)
R1/2 180 (28.4)
Not specified 20 (3.2)
Postoperative mortality
30-Day 75 (11.8)
90-Day 117 (18.5)
Abbreviations: AC, adenocarcinoma; DGH, district general hospital; LN, lymph node;
OGJ, oesophagogastric junction; Prh, private hospital; SCC, squamous cell carcinoma.
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Figure 1 Bar chart illustrating time interval from histological diagnosis to
surgical resection.
Table 2 Distribution of prognostic factors according to delay form
diagnosis to surgery (percentages in brackets)
Characteristic P-value
o21 days
(n¼84)
22–42
days
(n¼164)
43–63
days(n¼210)
464 days
(n¼174)
Age (years) 0.0255
o60 31 (36.9) 54 (32.9) 49 (23.3) 37 (21.3)
60–70 24 (28.6) 62 (37.8) 80 (38.1) 63 (36.2)
470 29 (34.5) 48 (29.3) 81 (38.6) 74 (42.5)
Gender 0.3681
Male 54 (64.3) 123 (75) 149 (71) 125 (71.8)
Female 30 (35.7) 41 (25) 61 (29) 49 (28.2)
Hospital type o0.0001
UHs 31 (36.9) 74 (45.1) 107 (51) 115 (66)
DGHs 45 (53.6) 84 (51.2) 101 (48.1) 58 (33.4)
PrHs 8 (9.5) 6 (3.7) 2 (0.9) 1 (0.6)
Tumour location 0.054
Upper/middle 15 (17.9) 19 (11.6) 27 (12.9) 14 (8.1)
Lower 35 (41.7) 54 (32.9) 69 (32.9) 52 (29.9)
OGJ 32 (38) 81 (49.4) 107 (50.9) 104 (59.8)
Not specified 2 (2.4) 10 (6.1) 7 (3.3) 4 (2.2)
Histology 0.0008
AC 54 (64.3) 118 (72) 154 (73.3) 149 (85.6)
SCC 30 (35.7) 46 (28) 56 (26.7) 25 (14.4)
Tumour grade 0.1699
WD 7 (8.4) 13 (7.9) 15 (7.1) 23 (13.2)
MD 37 (44) 64 (39) 81 (38.6) 55 (31.6)
PD 39 (46.4) 77 (47) 103 (49.1) 81 (46.6)
Not specified 1 (1.2) 10 (6.1) 11 (5.2) 15 (8.6)
Lymph-node
status
0.0556
LN  ve 32 (38.1) 41 (25) 70 (33.3) 68 (39.1)
LN +ve 52 (61.9) 123 (75) 137 (65.3) 104 (59.7)
Not specified 0 0 3 (1.4) 2 (1.1)
Resection 0.0097
R0 55 (65.5) 99 (60.4) 153 (72.9) 125 (71.8)
R1/2 28 (33.3) 63 (38.4) 49 (23.3) 41 (23.6)
Not specified 1 (1.2) 2 (1.2) 8 (3.8) 8 (4.6)
Postoperative
mortality
0.9716
30-day 11 (13) 19 (11.6) 24 (11.4) 22 (12.6)
90-day 16 (19) 33 (20.1) 37 (17.6) 32 (18.4)
Abbreviations: AC, adenocarcinoma; DGH, district general hospital; LN, lymph node;
OGJ, oesophagogastric junction; Prh, private hospital; SCC, squamous cell carcinoma;
UH, university hospitals. Significant P-values in bold.
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sOn univariate analysis a younger age at diagnosis, a well-
differentiated tumour, absence of lymph node involvement,
complete resection and a longer delay between diagnosis and
surgical resection were all associated with improved survival
(Table 3 and Figure 3). There were no significant differences in
median survival according to patients’ gender, the hospital type at
which the surgery was performed, tumour location or histological
tumour type. Multivariate analysis revealed that a longer delay
between diagnosis and surgery was not an independent prognostic
factor, whereas a significant survival benefit persisted for patients
of younger age, complete resection of the tumour and absence of
lymph-node involvement (Table 4).
DISCUSSION
The time interval between diagnosis and surgery was with a median
delay of 47 days (6. 7 weeks) comparatively longer than reported in
previous studies. Martin et al (1997) examined delays in patients with
0%
20%
40%
60%
80%
100%
21 days 22 – 42 days 43 – 63 days 64 days
Stage 0/I Stage IIA Stage IIB Stage III Stage IV
Figure 2 Percentage bar chart showing the distribution of disease stage
according to the time interval from histological diagnosis to surgical
resection.
Table 3 HRs with 95% confidence intervals from univariate analysis:
median survival according to individual prognostic factors and delay to
surgical resection
Characteristics
Median
survival
(months) P-value HR 95% CI
Delay (days) 0.0041
0–21 12.6 1
22–42 13.29 0.962 (0.726–1.274)
43–63 15.19 0.817 (0.607–1.074)
464 19 0.654 (0.454–0.845)
Age (years) 0.04
o60 18.02 1
60–70 14.86 1.26 (1.017–1.558)
470 13.61 1.305 (1.053–1.614)
Gender 0.354
Female 16.04 1
Male 15.29 1.093 (0.907–1.314)
Hospital type 0.926
UHs 16.04 1
DGHs 14.76 1.008 (0.849–1.197)
Tumour location 0.369
Upper+middle 12.56 1
Lower 15.19 0.862 (0.641–1.145)
OGJ 16.24 0.825 (0.614–1.080)
Histology 0.578
AC 15.52 1
SCC 14.93 1.057 (0.868–1.289)
Tumour grade 0.025
WD 23.54 1
MD 16.41 1.185 (0.871–1.588)
PD 12.76 1.437 (1.054–1.828)
LN status o0.0001
LN –ve 29.6 1
LN +ve 12.76 2.268 (1.847–2.624)
Resection o0.0001
R0 19.1 1
R1/2 9.86 2.324 (2.474–3.921)
Abbreviations: AC, adenocarcinoma; CI, confidence interval; DGH, district general
hospital; HR, hazard ratio; LN, lymph node; OGJ, oesophagogastric junction; Prh,
private hospital; SCC, squamous cell carcinoma; UH, university hospitals. Significant
P-values in bold.
0 12 24 36 48 60 72 84 96 108 120
0
25
50
75
100
%
%
%
  0 – 21 days
22 – 42 days
43 – 63 days
  > 64 days
P = 0.0041
0 12 24 36 48 60 72 84 96 108 120
0
25
50
75
100  LN − ve
 LN + ve
P < 0.0001
0 12 24 36 48 60 72 84 96 108 120
0
25
50
75
100
R0
R1/R2
P < 0.0001
Months
Figure 3 Kaplan–Meier survival curves of 632 patients with cancer of
the oesophagus or OGJ according to interval from histological diagnosis to
surgical resection (top), lymph-node status (middle) and completeness of
resection (‘R0’ – complete resection without involved margins on histology,
‘R1/R2’ – micro- or macroscopically incomplete resection) (bottom).
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soesophagogastric cancer presenting to the surgical department of a
large teaching hospital in the UK and found a median delay of 3.9
weeks and the prospective Scottish audit of gastric and oesophageal
cancer reported a delay of more than 1 month from establishing a
histological diagnosis to surgical resection in 45% of patients, whereas
in this study 76% of patients waited longer than 4 weeks.
Despite the relatively large difference in time interval between
diagnosis and surgical resection in this retrospective study ranging
from less than 3 weeks to more than 9 weeks, we did not find any
detrimental effect of delays on survival. The most significant
adverse prognostic factors influencing long-term survival in the
patient group examined were involvement of local lymph nodes
and the inability to achieve a complete resection, confirming
results of previous studies (Lieberman et al, 1995; Dexter et al,
2001; Butsch et al, 2002; Hofstetter et al, 2002).
What is commonly described and perceived by health autho-
rities as ‘waiting time’ between diagnosis and treatment,
constitutes a combination of important steps in the decision-
making processes leading to recommendation of the best
therapeutic approach for an individual patient. This process
generally includes thorough evaluation of the extent of the disease
through staging investigations, assessment of the patients’ co-
morbidity and multidisciplinary case discussion. A relation
between preoperative staging strategy employed and survival has
been observed in previous studies. Hofstetter et al (2002) noted in
their report on treatment outcomes of resected oesophageal cancer
that the group of patients who were preoperatively staged with
endoscopic ultrasound had a significantly improved survival.
Gilbert et al (2002) found in the Scottish audit of gastric and
oesophageal cancer 1997–2000 that patients in whom no regional
disease was found with a combination of CT and laparoscopy or
endoscopic ultrasound had significantly improved survival post
surgery.
Although reasons for a delay between diagnosis and surgery or
the type of staging investigations used could not be explored in
this study, treatment delays are likely multifactorial rather than
simply delays in service provision. In this study, younger patients
were operated sooner after their diagnosis, but were also more
likely to have had only an incomplete resection of the tumour.
Patients with a longer time interval between tumour biopsy and
surgical resection were less likely to have disease that had
metastasised beyond regional lymph nodes, when surgery can
only be regarded as palliative. It is important to note that with a
median survival of only 9.8 months patients whose tumour could
not be completely excised had a similar poor prognosis than
patients who receive only palliative treatment (Frenken, 2001; Ross
et al, 2002).
We conclude that patients who waited longer for their
operation were more appropriately selected for the surgical
treatment approach. Recording of the staging investigations used
before surgery would give valuable information for future
research. Regarding the use of neo-adjuvant chemotherapy,
we found that delays equivalent to the time required to give two
cycles of chemotherapy will not adversely affect the chance of cure
and emphasise that neo-adjuvant chemotherapy is now the
accepted standard of care for most patients with this type of
cancer.
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